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THEuse of a radioactive compound as an aid to the diagnosis of an internal
cancer would be highly desirable. Previous studies carried out in this laboratory have shown that with certain S35-labeled disulfonamido derivatives of fluorene
and biphenyl there is an evident difference in the distribution ofthese compounds between tumor-bearing and tumor-free animal organisms. The most promising results have been obtained with disodiumfluorene-2,7-disulfonate_S3.1(Argus, 1953)
and sulfonated derivative offluorene-2,7-di(sulfonamido-2-naphthalene)_S35(Argus and Hewson, 1954) 1955). Both compounds have been tested in tumor-bearing and tumor-free mice and at each time period studied (2, 8 and 32 hours) the ratios
of localization in tumor tissue compared to the liver, spleen and also kidneys, blood and muscle were greatly increased.
On the other hand, an interesting observation has been made with fluorene-2
7-di(sulfonamido-2-naphthalene)_S35 (Argus, Hewson and Ray, 1956) and bi-
phenyl-4,4'-di(sulfonamido-benzene_S35-4-sulfonamide) (Argus, Seepe, Gutierrez,
Hewson and Ray, 1958), which have been localized in the liver and spleen of
tumor-free mice to a greater extent than in tumor-bearers.
Fluorene-2,7-di(sulfonamido-2-naphthalene)_S35 showed the same behavior in
hamsters with and without transplanted sarcoma (Argus, Lemasters, Gutierrez
and Ray, 1957). Furthermore, when the tumors were removed the concentration
ofradioactivity in the liver and spleen returned to the level found in tumor-free
animals. The same perception has beenreported for male Wistar rats with Walker
carcinosarcoma 256 (Argus, Seepe, Kane and Ray, 1958; Argus, 1961). To determine if, in the presence of tumor, the decreased uptake offluorene-2, 7-di(sulfonamido-2-na,phthalene)_S35 by the liver and spleen is a general stress
phenomenon, the distribution of this compound has been examined in rats and
mice of both sexes after total whole body irradiation of 150 r (Argus, Kane and
Ray, 1960) and after cortisone treatment (Malejka, Argus and Ray, 1961). The
results of these experiments showed that the presence of tumor in animals is
responsible for the differential uptake of disulfonamide by the liver and spleen. In the present study two new substances were prepared and examined in
tumor-bearing and tumor-free Wistar rats in an attempt to find a favorable liver-
spleen or tumor localization. These were fluorene-2,7-di(sulfonamidobenzene-S35-
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4-sulfonamide), 1, and a compound, the analysis of which corresponds to disodium
fluorenone-X-nitroso-2,7-di(sulfonamidobenzene-S35-4-sulfonate) dihydrate, 11.
,///\-HN-02S \/\//\-SO2-NH
2FIN02S- _SO2NH2
0
.\-HN_O2S_//\/ ////\-SO2-NH -NO
Nao3S-\\/ _SO3Na 2H20
Radioactive S-3-1.
The chemical structures of both compounds are closely related to the group
of high molecular weight disulfonamides which were reported on previously.
Compound I is ananalog of abiphenyl derivative which was tested in mice (Argus,
Seepe, Gutierrez, Hewson and Ray, 1958), and compound 11 was obtained from I
by reaction with nitrous anhydride, since this method was reported to be satis-
factory in the case of carboxy amides extremely resistant to hydrolysis (Hurd
andSowden, 1938 ; Sperber, Papa and Schwenk, 1948). However, in the described
case this resulted, in addition to removal ofthe amido groups, in a compound the
analysis of which corresponds to disodium fluorenone-X-nitroso-2,7-di(sulfonam-
idobenzene_S35-4-sulfonate) dihydrate, indicating supplementary introduction of a
nitroso group and oxidation in the 9 position. While this was a more profound
change than we had intended, it-, nevertheless, seemed of interest to compare the
behavior of this less usual derivative with those previously studied.
MATERIALS AND METHODS
Fluorene-2)7-disulfonyl chloride-S35.-The procedure described previously
(Argus and Hewson, 1954) was employed, but 50 millicuries ofsulfur-35 were used
with the same quantities of other re.-,ctants. The yield of crude material wa's 25 g.
(71 per cent oftheory). Recrystallization from toluene gave 6 g. ofproduct (17
per cent oftheory), melting at 220-221' ; specific activity was not determined on
this intermediate.
Fluorene-2.7-di(sulfonamidobenzene-S35-4-8,Ulfonamide), I.-Sulfanilamide, 14-2
g. (0-082 moles) was dissolved in 120 ml. methyl ethyl ketone at 55-60'. The
solution was stirred and maintained at 60' throughout the addition (15 minutes)
offluorene-2,7-disulfonyl chloride-S35, 6 g. (0-016 moles), after which the tempera-
ture ofthe water bath was raised to and maintained at 95' for 7 hours. The white,
thick reaction mixture was allowed to cool to room temperature, the precipitate
was collected, washed free of sulfanilamide hydrochloride with hot distilled water,
and dried overphosphoruspentoxide. Theyield ofcrude material was 10 g. (95-41
per cent oftheory), melting point 280-282'. Recrystallization from dioxane and
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then 95 per cent ethanol gave 6 g. (5-i.25 per cent of theorv) of white product
melting at 290-292' and having a specific activity of 7100' disintegrations per
second per mg. (0-19 Itc per ing.).
Analy8i,3.-Calculated for (125 22 4S40 C, 47-32; H, 3-49; N, 8-82 ; S, 20-21.
Found: C, 47-55 ; H, 3-48 ; N, 8-92 ; S, 20-39.
Di8odium fluorenone-X-nitrO8O-2,7-di(,sulfonamidobenzene-835-4-8ulfonate) dihy-
drate II.-Fluorene-2 7-di(sulfonamido-benzene-835-4-sulfonamide), 4-5 g. (0-0('7
moles), was suspended in 35 ml. glacial acetic acid. The suspension was treated
at 5' with nitroiis anhydride (generated by the action of arsenic trioxide, 30 g.
(0-15moles) and concentrated nitric acid _99g. (0-45moles)) until the material dis-
solved (aboiit 30 minutes). A lively evolution ofnitrogen occurred almost imme-
diately after introdtiction of the nitrous anhydride. The reaction mixture was left
for an hour in ice, and then at room temperature under a well ventilated hood for
at least 4 hours to remove the excess of gas from the solution. To the light yellow
acid solution (filtered if not quite clear), a saturated solution of sodium acetate
was addedslowlywithstirring tobrinV the p.R to about 9. Thus, theyellow sodium
salt of sulfonic acid was precipitated and collected. The yield was 1-5 g. (30-61
per cent oftheory) with decomposition point about 300'. The double extraction
ofimptirities with absolute ethanol gave 1. g. (20-41 per cent oftheory) ofinsoluble
residue melting at 283' and having a specific activity of 5300 disintegrations per
second per mg. (0-14 /ic per mg.). It retained two molecules of water very ten-
aciously.
Analy8i&-C'alculated for C25H19N3.S4014Na2: C, 39-53; H, 2-52; N, 5-53; 8, 16-88;
Na, 6-05.
Found: C, 39-15; H, 2-62 ; N, 5-39; 8, 15-96 Na, 5.82.
The sodium salt shaken with Amberlite IR-120 gave the free sulfonic acid deriva-
tive as a glass, which decomposed at 2_95'. It was not f-Lirther examined, but was
converted iiito the mono-p-toluidine salt, which melted at 235'. This retained
one molecule of water.
Analy8is.-Calculated for C32H2,,N C, 47-75 ; H, 3-51 N, 6-96 ; 8, 15-94.
Found: C, 47-91 ; H, 3-99 ; N, 7-30; 8, 15-25.
Animal experiment8.-A total of '24 male Wistar rats, weanlings, was used;
I I were employed for the subcutaneous transplantation of Walker carcinosarcoma
256, now in its 115th generation transplant in this laboratory ; 13 tumor-free rats
served as control groups. When the tumors were 10-12 days old, and averaged
12 g. in weight, the radioactive compounds were administered by tail vein injec-
tions. Each rat was given 1-2 ml. 0-05 N sodium hydroxide containing 12 mg.
fliiorene---),7-di(sulfonamidobenzene-835-4-sulfonamide), 1, or disodium fluorenone-
X-nitroso-2, 7-di(sulfonamidobenzene-S35-4-sulfonate) dihydrate, 11, and then
placed in an individual metabolism caae and killed 6 hours following administra
tioii of the compounds. Concentration and per cent recovery of radioactive
material in tissues and excreta of rats were determined by methods previously
described (Argus, Kane and Ray, 1960). Radioactivity memurements were
made in the gas-flow GM counter of the low background automatic sample
changer, Model Cllr), with decade scaler Model 181A and printer Model CIIIB,
from the Nuclear (__',hicago Corporation. The efficiencv of the instrument was
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RESULTS AND DISCUSSION
The complete tissue distribution of fluorene-2,7-di(sulfonamidobenzene-S35-4-
sulfonamide), 1, and disodium fluorenone-X-nitroso-2,7-di(sulfonamidobenzene-
S35-4-sulfonate) dihydrate, 11, between tumor-bearing and tumor-free Wistarrats,
was compared. Since previous experiments have shown a 6 hours time interval to
be relativelv effective for the distribution of disulfonamido derivatives of fluorene
(Argus, Kane and Ray, 1960; Malejka, Argus and Ray, 1961), the present inves-
tige,tion was conducted under the same condition. The details of these studies for
compounds I and 11 are shown in Table 1. Both concentrations, expressed as /tg.
TABLE I.-Distribution of Radioactivity in Tumor-bearing and Tumor-free Wistar
Rats 6 Hoursfollowing Intravenous Injection ofFluorene-2,7-di(Sulfonamido-
benzene-S35-4-8ulfonamide), I, and Disodium Fluorenone-X-Nitroso-2,7-di(sul-
fonamidobenzene-S35-4-sulfonate) Dihydrate, II*
Tumor-bearing rats
r I
Compound It Compound Ilt
r _A_._,% I
pg./g. Per cent pg.Ig. Per cent
2 0- 08 1 0- 06
3 0.10 40 1- 58
26 1- 27 18 1.09
5 0- 03 26 0-16
I <0.01 8 0- 08
15 0-12 45 0- 46
3 <0-01 5 0.01
24 4- 84 51 10- 95
2 0- 02 9 0- 07
21 0- 32 20 0- 26
503 24-90 272 13-64
1412 67-08 970 53-93
4 1-75 9 4-21
153 1-27 229 1.95
407 0-30 53t 0-06
1511 0-92 27 3-02
Tumor-free rats
r
Compound It Compound ll§
r
yg./g. Per cent ug./g. Per cent
<3t 0- 08 <It 0- 02
2 0- 06 39t 1-17
40 2
- 00 17 0- 73
9 0.05 24 0-12
4 0.01 8 0- 03
16 0.15 41 0- 37
2 <0-01 9 0- 02
26 5- 13 53 8- 47
2 0- 02 13 0.10
10 0- 12 40 0- 45
572 21-87 247 11-99
1277 68-30 1078 55-19
3 1-72 13 5-57
44 0-37 158 1-33
9 0-03 252t 1-52
Tissue
Blood cellsT
Blood plasmaT
Liver
Lung
Spleen
Kidney
Thymus
Skin
Leg muscle
Stomach + contents
Small intestine+contents
Large intestine+contents
Carcass
UrineT
Feces
Tumor
Total 103
- 02 91- 53 . 99- 92 87-08
* Dose of S35-labeled compound I or 11-12 mg. for each rat.
t Average value from 5 rats.
t Average value from 6 rats.
§ Average value from 7 rats.
Average value from 4 rats.
Concentration in ug. compound/ml. ; others expressed in pg. compound/g. tissue.
of compound per g. tissue or ml. blood or urine, and percentages of administered
dose recovered are given.
Differences between the distribution of the two substances are evident. While
the values for blood cells and bloodplasma forfluorene-2,7-di(sulfonamidobenzene- 835-4-sulfonamide) are relatively small and nearly the same, there is a great difference between these values for the second compound, the concentration in
plasma being 40 times greater than in red blood cells. This is a key to the rate
ofdistr'ibution of these compounds in the animal body. Compound 11 is absorbed
from the blood at a slower rate than 1. The filtration ofcompound IIthrough the
liver is slower than I and is not changed by the presence of tumor. Consequently,DANUTA MALEJKA
elimination into the small intestine is less. The values found for II in the small
intestines and their contents are about one half those found for I. This observa-
tion is also supported by the presence of a greater amount of compound I in the
large intestines and their contents. The values for feces vary as usual for a short
period. The distribution in the skin and carcass for both compounds seems to be
somewhat related to this phenomenon since considerably more radioactivity is
found for II in these tissues.
Considering differences in localization of S35-labeled compounds between
experimental and control animals, the ratios of concentration of radioactivity in
blood cells, blood plasma, liver, spleen and uring of tumor-free Wistar rats to the
concentration in the same tissues of tumor-bearers 6 hours following intravenous
injection ofcompounds I and II are presented in Table II. In most cases the ratio
TABLE II.-Ratios of Concentration of Radioactivity in the Tissues of Tumorfree
Wistar Rats to the Concentration in Tissues of Tumor-bearing Wistar Rats 6
hours Follouwing Intravenous Injection of S35-labeled Compounds*
Blood Blood
Compound cells plasma Liver Spleen Urine
Fluorene-2,7-di(sulfon-
amidobenzene-S35-4-
sulfonamide) (I)
Ratio av. cont.t 1-18 0-67 1-54 4 00 0-29
iav. exp.t
Probability§ -04 _0 2 ~01 0 001<P<0.01 0 001
Mean dif. ± std. dev. 0'40±0.45 1.0-±0.75 14-0±7-7 3 0±0-88 109±22-6
Disodium fluorenone-
X-nitroso-2,7-di
(sulfonamidobenzene-
S35-4-sulfonate)
dihydrate (II)
Ratio (av. cont.¶T 0-60 0-98 0 94 1.00 0-69
av. exp.t
Probability§ . . 02<P<0.3 0'8<P<0'9 06<P<07 09<P<10 02<P<03
Meandif. ± std. dev. 0-660-55 0-8±5-1 1-0±2-1 0±0-42 71-0±52-7
* Dose of S35-labeled compound I or II-12 mg. for each rat.
t Average value from 6 rats.
I Average value from 5 rats.
§ Based on null hypothesis for true difference between experimental (tumor-bearing) and control
(tumor-free) groups' values.
¶ Average value from 7 rats and 5 rats in the cases of blood cells and plasma.
is close to 1.00, or reveals no significant difference (0.2 < P < 0.3) in compound
localization between control and experimental organs. Exceptions are ratios for
the liver and spleen ofcompound I. The liver ofcontrol rats took 1.54 times more
radioactive substance than liver of experimental animals. The uptake of radio-
activity by control spleen is 4-00 times greater than by the experimental organ.
Both these values indicate an evident functional change of the liver and spleen
caused by the presence of Walker carcinosarcoma 256, and offer, therefore, a
possible diagnostic tool. Comparing values (2.52 for the liver and 1.72 for the
spleen) which were reported by Argus (1961) for fiuorene-2,7-di(sulfonamido-2-
naphthalene)-S35, the uptake of fiuorene-2,7-di(sulfonamidobenzene-S35-4-sulfon-
amide) by control liver is somewhat less, but the ratio for the spleen is considerably
increased. Probability values (_0.1 and 0.001 < P < 0.01) appear to be signifi-
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cant. The most striking difference between control and experimental animals is
found in the urine after a single injectioii offluorene-2,7-di(sulfonamidobenzene-
S35-4-sulfonamide), 1. The increased excretion of compound to urine by experi-
mental rats is significant (P
- 0-001), and together with the decreased values of
concentration in the liver and spleen of tumor-bearers indicate an affected meta-
bolism of this S35-labeled compound in the presence of tumor.
A more favorable localization in tumor is found using compound 11. This
observation is in agreement with previous findings in mice (Argus, 1953; Argus
and Hewson, 1954), that the presenIce of sulfonic acid groups in the fluorene or its
derivative molecule increased the concentration of radioactivity in tumor. The
molecular weight of the compound is also to be considered : the sulfonic acid
derivative investigated in the present study has the molecular weight falling be-
tween the compounds previously tested : fluorene-2,7-disulfonic acid-S35 (Argus,
1953) and sulfonated derivative of fluorene-2,7-di(sulfonamido-2-naphthalene)-S35
(Argusand Hewson, 1954). The data obtainedwith disodiumfluorenone-X-nitroso-
2,7-di(sulfonamidobenzene-S35-4-sulfonate) dihydrate show that for liver, lung,
spleen, thymus, leg muscle, stomach and carcass the ratio values are greater than
1-00 (see column 3 in Table 1). For organs of aparticularimportance such as liver
and spleen they are 1-50 and 3-37, respectively, thus revealing diagnostic
possibilities.
In conclusion, these studies in Wistar rats with Walker carcinosarcoma 256
appear to support previous postulates that compounds with primary sulfonamido
groups have a tendency to concentrate in the liver and spleen of tumor-free ani-
mals to a greater extent than in tumor-bearers. Secondly, sulfonic acid groups
provide a more favorable tumor localization than the sulfonamido groups. The
optimal number of sulfonic acid groups, their most effective position and the most
satisfactory sized molecule, however, have not yet been established.
SUMMARY
Two new radioactive compounds: fluorene-2,7-di(sulfonamidobenzene-S35-4-
sulfonamide), 1, and disodium fluorenone-X-nitroso-2,7-cli(sulfonamidobenzene-
S35-4-sulfonate) dihydrate, 11, have been prepared and their tissue distribution
following a single intravenous injection to tumor-bearing and tumor-free Wistar
rats has been studied. While the distribution of compound I is affected by the
presence of tumor, compound 11 shows no evident difference between experi-
mental and control organs. In the tumor-bearing rats this compound has, how-
ever, a greater concentration of radioactivity in tumor tissue as compared with
liver, leg muscle, carcass, spleen and thymus. Compound I has a tendency to
localize in the liver and spleen of control animals to a greater extent than in
tumor-bearers. The ratios found for the liver (1-54) and spleen (4-00), together with the considerably increased excretion ofthis compound in the urine ofexperi-
mental rats, indicate a possible diagnostic tool.
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